Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spectral MedicalEDTXF +0.40%7 Equity-to-Asset is -21.97 as of Jun. 2026. GuruFocus rates EDTXF with a GF Score™ of 7/100 and a GF Value™ of $0.58 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Spectral Medical ranks worse than 98.57% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Spectral Medical's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $-49.93 Mil. Spectral Medical's Total Assets for the quarter that ended in Jun. 2026 was $2.27 Mil.
Therefore, Spectral Medical's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was -21.97.
The historical rank and industry rank for Spectral Medical's Equity-to-Asset or its related term are showing as below:
EDTXF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -21.97 Med: 0 Max: 0.93
Current: -21.97
During the past 13 years, the highest Equity to Asset Ratio of Spectral Medical was 0.93. The lowest was -21.97. And the median was 0.00.
EDTXF's Equity-to-Asset is ranked worse than 98.57% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.595
vs EDTXF: -21.97
Spectral Medical (OTCPK:EDTXF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Spectral Medical Equity-to-Asset Related Terms
Spectral Medical Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Spectral Medical's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EDTXF vs TMO, DHR, NTRA: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Spectral Medical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spectral Medical Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Spectral Medical's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Spectral Medical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spectral Medical (EDTXF) has a Equity-to-Asset of -21.97 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Spectral Medical and its competitors. According to the industry distribution chart, Spectral Medical ranks #207 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 98.6%.
Is Spectral Medical's Equity-to-Asset too high?
Spectral Medical's current Equity-to-Asset is -21.97. Based on the distribution chart, Spectral Medical ranks #207 out of 210 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Spectral Medical has a GF Score™ of 7/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spectral Medical ranks #207 out of 210 companies for Equity-to-Asset. This places Spectral Medical in the lower half of its industry. The industry median Equity-to-Asset is 0.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.60, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Spectral Medical and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spectral Medical's current Equity-to-Asset is -21.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (EDTXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.58, compared to a current price of $0.92 — trading 58.6% above its estimated fair value. The current Equity-to-Asset is -21.97. Spectral Medical's overall GF Score™ is 7/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Spectral Medical (EDTXF), the current Equity-to-Asset is -21.97 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spectral Medical (EDTXF) Overvalued in 2026?
Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued.
The current stock price of $0.92 is trading 58.6% above its estimated GF Value™ of $0.58.
GuruFocus considers Spectral Medical to be Significantly Overvalued.
Key valuation signals for EDTXF:
Equity-to-Asset: -21.97
GF Value™: $0.58 vs. price of $0.92 (58.6% above fair value)
No single metric tells the full story. See the EDTXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
7GF Score
Get the complete analysis for EDTXF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDTXF has been successfully added to your 
